• Explore /
  • Poster
  • / VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.

VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.

Abstract Poster

Authors

null

Mark Christopher Markowski

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

Mark Christopher Markowski , Ronald F. Tutrone , Mario A. Eisenberger , Christopher Michael Pieczonka , Robert H. Getzenberg , Domingo Rodriguez , K. Gary Barnette , Mitchell S. Steiner , Daniel Saltzstein , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03752099

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5056)

DOI

10.1200/JCO.2021.39.15_suppl.5056

Abstract #

5056

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Mark Christopher Markowski

First Author: Mark Christopher Markowski

First Author: Sumit Kumar Subudhi

First Author: Benedito A. Carneiro